Drugs / HDIT101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04539483 | Oct 2020 → May 2023 | herpes labialis | Heidelberg ImmunoTherapeutics GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT04165122 | Nov 2019 → Aug 2021 | genital herpes | Heidelberg ImmunoTherapeutics GmbH | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDIT101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04165122 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection” NCT04539483 ↗ |
| Route | Intravenous | “single 2 g intravenous dose of HDIT101” PMID 41109488 ↗ Oct 2025 |